Diabetes remains the leading contributor to the development of chronic kidney disease (CKD) and end stage kidney disease, emphasizing the urgency of identifying barriers to early diagnosis and intervention. The AWARE-CKD in T2D study described the awareness, values, and preferences of physicians (general practitioners, endocrinologists, and nephrologists) and patients on the management of chronic kidney disease in patients with type 2 diabetes (CKD in T2D). The results of the survey study highlighted opportunities for improving CKD in T2D management, such as earlier referrals to nephrologists and additional education and clarity for physicians on urinary albumin testing for assessing kidney risk. More understanding of kidney risk progression is also vital for patients.

Real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) have both shown to improve glycemic outcomes in people with diabetes. The objective of the REAL-CGM-T1D study was to assess the real-world effectiveness of using rtCGM compared to using isCGM on HbA1c and CGM metrics in adults with type 1 diabetes (T1D). The study reported a greater reduction in HbA1c by 0.3%, higher percent time in target glucose range by 4.4%, lower percent time below target glucose range by 3.9%, and reduced glycemic variability in adults with T1D using rtCGM compared to a matched cohort of adults with T1D using isCGM. Initiating a rtCGM device compared to an isCGM device may be particularly effective when HbA1c is < 8.5% and when individuals are using multiple daily injection therapy. The findings from this retrospective study support the benefits and importance of real-time and predictive alerts for individuals with T1D. With the release of second and third generation isCGM systems that offer alerts for hypoglycemia, further investigations are warranted.